Proto oncogene protein c-akt inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Proto oncogene protein c-akt inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Proto oncogene protein c-akt inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Proto oncogene protein c-akt inhibitors: Overview
Protein kinase B (PKB), also known as Akt, is the collective name of a set of three serine/threonine-specific protein kinases that play key roles in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration. There are three different genes that encode isoforms of Protein kinase B. These three genes are referred to as AKT1, AKT2, and AKT3 and encode the RAC alpha, beta, and gamma serine/threonine protein kinases respectively. Akt isoforms are overexpressed in a variety of human tumors, and, at the genomic level, are amplified in gastric adenocarcinomas (Akt1), ovarian (Akt2), pancreatic (Akt2) and breast (Akt2) cancers. The Akt kinases regulate cellular survival and metabolism by binding and regulating many downstream effectors, e.g. Nuclear Factor-?B, Bcl-2 family proteins, master lysosomal regulator TFEB and murine double minute 2 (MDM2).
Report Highlights
This segment of the Proto oncogene protein c-akt inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Proto oncogene protein c-akt inhibitors Emerging Drugs
Further product details are provided in the report……..
Proto oncogene protein c-akt inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Proto oncogene protein c-akt inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Proto oncogene protein c-akt inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Proto oncogene protein c-akt inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto oncogene protein c-akt inhibitors drugs.
Proto oncogene protein c-akt inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Proto oncogene protein c-akt inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Proto oncogene protein c-akt inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Proto oncogene protein c-akt inhibitors: Overview
Protein kinase B (PKB), also known as Akt, is the collective name of a set of three serine/threonine-specific protein kinases that play key roles in multiple cellular processes such as glucose metabolism, apoptosis, cell proliferation, transcription, and cell migration. There are three different genes that encode isoforms of Protein kinase B. These three genes are referred to as AKT1, AKT2, and AKT3 and encode the RAC alpha, beta, and gamma serine/threonine protein kinases respectively. Akt isoforms are overexpressed in a variety of human tumors, and, at the genomic level, are amplified in gastric adenocarcinomas (Akt1), ovarian (Akt2), pancreatic (Akt2) and breast (Akt2) cancers. The Akt kinases regulate cellular survival and metabolism by binding and regulating many downstream effectors, e.g. Nuclear Factor-?B, Bcl-2 family proteins, master lysosomal regulator TFEB and murine double minute 2 (MDM2).
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Proto oncogene protein c-akt inhibitors R&D. The therapies under development are focused on novel approaches for Proto oncogene protein c-akt inhibitors.
This segment of the Proto oncogene protein c-akt inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Proto oncogene protein c-akt inhibitors Emerging Drugs
- MK 2206: Merck
- Ipatasertib: Genentech
Further product details are provided in the report……..
Proto oncogene protein c-akt inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Proto oncogene protein c-akt inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Proto oncogene protein c-akt inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Proto oncogene protein c-akt inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Proto oncogene protein c-akt inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto oncogene protein c-akt inhibitors drugs.
Proto oncogene protein c-akt inhibitors Report Insights
- Proto oncogene protein c-akt inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Proto oncogene protein c-akt inhibitors drugs?
- How many Proto oncogene protein c-akt inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proto oncogene protein c-akt inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Proto oncogene protein c-akt inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Proto oncogene protein c-akt inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Merck
- Genentech
- Signpath Pharma
- Kazia Therapeutics
- HUYA Bioscience International
- AstraZeneca
- Novartis Oncology
- Aytu BioPharma
- CURACLE
- Almac Discovery
- Taiho Pharmaceutical
- Astex Pharmaceuticals
- Prescient Therapeutics
- Laekna Therapeutics
- Tactical Therapeutics
- MK 2206
- Ipatasertib
- Curcumin liposomal
- Paxalisib
- Tucidinostat
- Capivasertib
- Miransertib
- Afuresertib
- Enzastaurin
- CU 05
- API-2
- Pravitinib
- Uprosertib
- ALM 301
- ARQ 751
- TAS 0612
- AT 13148
Introduction
Executive Summary
Proto oncogene protein c-akt inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Proto oncogene protein c-akt inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Ipatasertib: Genentech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MK 2206: Merck
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ARQ 751: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CU 05: CURACLE
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Proto oncogene protein c-akt inhibitors Key Companies
Proto oncogene protein c-akt inhibitors Key Products
Proto oncogene protein c-akt inhibitors- Unmet Needs
Proto oncogene protein c-akt inhibitors- Market Drivers and Barriers
Proto oncogene protein c-akt inhibitors- Future Perspectives and Conclusion
Proto oncogene protein c-akt inhibitors Analyst Views
Proto oncogene protein c-akt inhibitors Key Companies
Appendix
Executive Summary
Proto oncogene protein c-akt inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Proto oncogene protein c-akt inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Ipatasertib: Genentech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MK 2206: Merck
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
ARQ 751: Merck & Co
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
CU 05: CURACLE
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Proto oncogene protein c-akt inhibitors Key Companies
Proto oncogene protein c-akt inhibitors Key Products
Proto oncogene protein c-akt inhibitors- Unmet Needs
Proto oncogene protein c-akt inhibitors- Market Drivers and Barriers
Proto oncogene protein c-akt inhibitors- Future Perspectives and Conclusion
Proto oncogene protein c-akt inhibitors Analyst Views
Proto oncogene protein c-akt inhibitors Key Companies
Appendix